Share-based Payment Arrangement, Expense of NexImmune, Inc. from 31 Mar 2020 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NexImmune, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Jun 2024.
  • NexImmune, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2024 was $280,542, a 72% decline year-over-year.
  • NexImmune, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2024 was $2,348,890, a 51% decline year-over-year.
  • NexImmune, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,553,626, a 39% decline from 2022.
  • NexImmune, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,870,364, a 1.8% decline from 2021.
  • NexImmune, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5,979,784, a 391% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NexImmune, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $2,348,890 $280,542 -$710,591 -72% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $3,059,481 $348,301 -$494,145 -59% 01 Jan 2024 31 Mar 2024 10-Q 20 May 2024 2024 Q1
Q4 2023 $3,553,626 $614,154 -$863,822 -58% 01 Oct 2023 31 Dec 2023 10-K 16 Apr 2024 2023 FY
Q3 2023 $4,417,448 $1,105,893 -$331,595 -23% 01 Jul 2023 30 Sep 2023 10-Q 17 Nov 2023 2023 Q3
Q2 2023 $4,749,043 $991,133 -$317,915 -24% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $5,066,958 $842,446 -$803,406 -49% 01 Jan 2023 31 Mar 2023 10-Q 20 May 2024 2024 Q1
Q4 2022 $5,870,364 $1,477,976 -$192,453 -12% 01 Oct 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
Q3 2022 $6,062,817 $1,437,488 -$190,942 -12% 01 Jul 2022 30 Sep 2022 10-Q 17 Nov 2023 2023 Q3
Q2 2022 $6,253,759 $1,309,048 -$174,433 -12% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $6,428,192 $1,645,852 +$448,408 +37% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $5,979,784 $1,670,429 +$1,396,445 +510% 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
Q3 2021 $4,583,339 $1,628,430 +$1,343,972 +472% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $3,239,367 $1,483,481 +$1,143,691 +337% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $2,095,676 $1,197,444 +$878,482 +275% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $1,217,194 $273,984 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
Q3 2020 $284,458 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $339,790 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $318,962 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1

NexImmune, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $3,553,626 -$2,316,738 -39% 01 Jan 2023 31 Dec 2023 10-K 16 Apr 2024 2023 FY
2022 $5,870,364 -$109,420 -1.8% 01 Jan 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
2021 $5,979,784 +$4,762,590 +391% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
2020 $1,217,194 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.